Lumateperone: First Approval

@article{Blair2020LumateperoneFA,
  title={Lumateperone: First Approval},
  author={H. Blair},
  journal={Drugs},
  year={2020},
  volume={80},
  pages={417-423}
}
  • H. Blair
  • Published 2020
  • Medicine
  • Drugs
  • Lumateperone (Caplyta ® ) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders. Lumateperone is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate. In December 2019, lumateperone received its first global approval in the USA for the treatment of schizophrenia in adults. The drug is also under clinical… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 29 REFERENCES
    Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
    6
    Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
    8
    Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
    42
    ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
    32
    Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia [abstract no. W203 plus poster
    • 2019
    ITI-007/ITI-722: a new approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases [abstract
    • 2009
    Efficacy and safety of lumateperone tosylate 42 mg in the treatment of schizophrenia: a pooled analysis of phase 2 and 3 studies [abstract no. P.671
    • 2019